Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and tolerability of V114 with Prevnar 13 in healthy infants; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)
• V114 (15-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2022-05-10